Fast multiparametric MR imaging as early biomarkers of Alzheimer's Disease
Fast multiparametric MR imaging as early biomarkers of Alzheimer's Disease
批准号:
9808931
负责人:
Deqiang Qiu
金额:
$23.4万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-08-15 至 2021-04-30
关键词:
3-DimensionalAgeAgingAlzheimer&aposs DiseaseAlzheimer’s disease biomarkerAmyloidAmyloid beta-ProteinAtrophicBiological AssayBiological MarkersBrain regionCerebrospinal FluidClassificationClinical TrialsCognitionCognitiveCommunitiesDementiaDetectionDevelopmentDiagnosisDiagnosticEconomicsEnsureEtiologyFailureFingerprintGoalsHippocampus (Brain)ImageIndividualInfrastructureMachine LearningMagnetic ResonanceMagnetic Resonance ImagingMagnetismMapsMeasurementMeasuresMethodsMorphologyMotionMulticenter StudiesNeuropsychological TestsNeuropsychologyParticipantPathologic ProcessesPatientsPhenotypePositron-Emission TomographyPredispositionPreventionProcessProtocols documentationReportingResearchResearch PersonnelResearch TechnicsResolutionSamplingScanningScheduleSeveritiesStructureTechniquesTestingThickThree-dimensional analysisTimeUniversitiesagedbasecandidate markerdisease diagnosisearly detection biomarkersearly screeningeffective therapyhealthy volunteerhigh risklearning strategymild cognitive impairmentneuroimagingnormal agingoutcome forecastpredictive markerpredictive modelingprognosticsocialsuccesstau Proteins
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Without a cure or prevention, Alzheimer's Disease (AD) rapidly will become an overwhelming economic and
social burden. With the failure of multiple clinical trials targeting reduction of beta-amyloid (Aβ) burden and in
general the stagnation of the development of effective treatment for AD, AD community believes that underlying
causes of AD must be attacked before emergence of the cognitive phenotype. In this context, the development
of predictive biomarkers and models is critical for identifying patients with high risk of rapid progression along
the AD continuum, i.e. transitioning from normal cognition to mild cognitive impairment (MCI) and from MCI to
dementia. Previous AD research has primarily been utilizing magnetic resonance imaging (MRI) for assessing
morphological changes. Our preliminary results and other studies have shown that quantitative MR parameters
such T1, T2, the magnetic susceptibility values are sensitive to normal ageing process and AD. However, their
wide spread in AD research protocols has been limited due to scan time constraints. The overarching goal of the
proposal is to establish a fast MR technique that does not increase overall scan time of a conventional MR
protocol; and in addition to providing all the information the conventional protocol provides, it will also provide
multiple quantitative parametric measurements specifically targeted to the needs of AD diagnosis and prognosis.
We will 1) develop a fast and motion-insensitive MR technique (M3FAST-ECHO) that can generate multiple
quantitative parameters within 10 minutes; 2) validate the volumetric measurement and microhemorrhage
assessment from the synthetic 3D T1-weighted and the susceptibility weighted imaging from M3FAST-ECHO
against standard ADNI protocol in 30 patients with mild cognitive impairment and 30 aged matched cognitively
normal subjects; 3) compare quantitative T1, T2* and quantitative susceptibility values in 30 MCI patients and
30 aged matched cognitively normal subjects, and to correlate these metrics with neuropsychological
measurements in the participants. The successful completion of the aims will result in a fast MR technique that
provides multiple parametric MR maps without increasing overall scan time, and provide preliminary results for
establishing values of quantitative MR parametric maps as sensitive biomarkers of AD. This will greatly enhance
our ability to evaluate and screen for early predictive biomarkers of Alzheimer's Disease. The inter-disciplinary
team and infrastructure for AD research at Emory will ensure successful execution of the study and dissemination
of the developed techniques to the entire AD research community.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cerebral hemodynamic impairment in symptomatic and asymptomatic Alzheimer's Disease
-
批准号:10370529
-
项目类别:
-
资助金额:$85.75万
-
财政年份:2022
-
负责人:Deqiang Qiu
-
依托单位:
Cerebral hemodynamic impairment in symptomatic and asymptomatic Alzheimer's Disease
-
批准号:10552557
-
项目类别:
-
资助金额:$86.22万
-
财政年份:2022
-
负责人:Deqiang Qiu
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: